Paroxysmal Atrial Fibrillation Treatment Market Size [2030]
Paroxysmal Atrial Fibrillation Treatment Market Size [2030]
Segments - Global Paroxysmal Atrial Fibrillation Treatment Market by Treatment Type (Pharmacological Treatment, Non-pharmacological Treatment, Maze Surgery, and Electric Cardioversion), Technology (Radiofrequency, Laser, Cryotherapy, and Others), End-user (Hospitals, Specialty Clinics, and Others), and Regions (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2022-2030
Upcoming
| Report ID :HC-5458
| 4.5 Rating
| 84 Reviews
| 263 Pages
| Format :
Report Description
Paroxysmal Atrial Fibrillation Treatment Market Outlook
The global paroxysmal atrial fibrillation treatment market was estimated at USD 4,822.5 Mn in 2021 and is anticipated to reach USD 10,040.2 Mn by 2030, expanding at a CAGR of 8.8% during the forecast period.
Paroxysmal atrial fibrillation is a condition experiencing an irregular heartbeat, which results in cardiac arrhythmia. This type of atrial fibrillation occurs occasionally and stops spontaneously. Paroxysmal atrial fibrillation causes damage to the electrical pulses, resulting in irregular heartbeat in the patient.
The major symptoms of Paroxysmal atrial fibrillation include chest pain, shortness of breath, fatigue, and others. Paroxysmal atrial fibrillation can cause stroke or heart-related disease conditions in the patient. The type of heart condition is treated with different classes of oral drugs such as anti-arrhythmic and anti-coagulant.
Flecainide, sotalol, and propafenone are some oral medicines used for the treatment of Paroxysmal atrial fibrillation. The treatment includes minimally invasive procedures such as catheter ablation, electric cardioversion, maze surgery, and others.
Macro-economic Factors
Healthcare Spending
Governments across the globe are investing in the healthcare industry to increase real per capita healthcare spending. Healthcare expenditure plays an important role in the treatment of several diseases, owing to the high cost of treatments for the different types of diseases.
The incremental cost for atrial fibrillation treatment is in between the range of USD 6.0 to USD 26.0 billion. Hospitalization is a major driver of the rising cost of atrial fibrillation treatment. According to National Health Estimates, the governmental share in total health expenditure increased from 28.6% in the year 2018 to 40.6% in 2019.
National Healthcare Spending is expected to be USD 4.1 trillion in 2020. Hospital expenditure increased up to USD 1,270.1 Billion in 2020, which is faster than the 6.3% growth in 2019.
Lifestyle Diseases
Incidences of lifestyle disease, such as heart-related and diabetes condition, is rising, as a majority of the population suffers from chronic disease condition, owing to their poor eating habits, and sedentary lifestyle, resulting in high cholesterol and arrhythmic condition. An increase in the number of people suffering from arrhythmia and heart-related disorders boosts mortality rates caused by stroke.
The arrhythmic condition accounts for 15% to 20% of overall deaths globally. Thus, the development of effective diagnosis and treatment for restoring abnormal rhythm in patients is integral. Electric cardioversion therapy, catheter ablation, and oral anticoagulants are preferred treatments for normalizing irregular heartbeats in patients with Paroxysmal atrial fibrillation conditions. Rising incidences of arrhythmia fuel the need for Paroxysmal atrial fibrillation.
Paroxysmal Atrial Fibrillation Treatment Market Dynamics
Market Driver- Increasing prevalence of Paroxysmal atrial fibrillation in elderly patients
Elderly patients with an age group above 80 years are prone to heart-related conditions such as cardiac arrhythmia, owing to aging and weak immunity. The elderly population usually develops a high risk for cardiovascular diseases. Thus, rising cardiovascular cases among elderly patients propel the demand for Paroxysmal atrial fibrillation treatment.
Different medications and therapies are available for Paroxysmal atrial fibrillation treatment. Amiodarone is an antiarrhythmic medication administered along with cardioversion therapy, which effectively controls and maintains a normal heart rate. Thus, the increasing prevalence of Paroxysmal atrial fibrillation, especially arrhythmia among the elderly population is driving the market.
Market Driver- Rising prevalence of strokes, heart failure
Bad eating habits and sedentary lifestyles mostly result in a high risk of developing heart-related disorders. Heart failure or stroke commonly occurs as a result of serious complications of Paroxysmal atrial fibrillation. These heart conditions are mainly caused by abnormal electrical pathways and irregular heartbeat with the pumping of inefficient oxygen-rich blood in the body.
Thus, rising cases of heart failure or stroke among patients is a key factor boosting the demand for Paroxysmal atrial fibrillation treatment. Electrical cardioversion, catheter ablation, and oral medication are some remedies to lower the risk of stroke and restore irregular rhythm in a patient.
Market Restraint- Lack of skilled professionals for Paroxysmal atrial fibrillation treatment
The Paroxysmal atrial fibrillation procedure is used to treat arrhythmia in heart patients. Different types of catheter ablation are performed for the Paroxysmal atrial fibrillation treatment. The radiofrequency ablation procedure uses radio frequency waves for treating arrhythmic conditions. Whereas, cryoablation procedures use extreme cold to freeze and destroy damaged tissue causing the arrhythmia.
These procedures use advanced ablation techniques for normalizing arrhythmic heart rates, which require a team of skilled healthcare professionals. For instance, Stanford Healthcare organization offers advanced Paroxysmal atrial fibrillation treatment with a group of skilled doctors for treating arrhythmia in patients.
Thus, the lack of skilled medical professionals handling diagnostic devices for arrhythmia treatment reduces the efficacy of the diagnosis result. Thus, the lack of skilled professionals for treating arrhythmia is restraining the growth of the market.
Market Opportunity- Technological advancement in Paroxysmal atrial fibrillation
Paroxysmal atrial fibrillation is a common arrhythmia condition diagnosed with cardiac monitoring devices. These cardiac monitoring devices are incorporated with technologies for offering accurate detection of arrhythmia in patients.
For instance, electrocardiogram patch monitors are validated wearable digital devices incorporated with advanced Technology, offering accuracy and high diagnostic yield than traditional Holter monitors. The devices are used along with smartphone applications that ensure accurate monitoring of the arrhythmic heart rate in patients.
Furthermore, the manufacturers of cardiac monitoring devices are focusing on the adoption of Artificial Intelligence (AI) and other advanced technologies in cardiac monitoring devices, which can help reduce complications in patients. Implantable cardiac monitoring devices are developed along with AI that helps in accurate diagnosis and prevent a high risk of stroke in cardiac arrhythmia patients.
Scope of Paroxysmal Atrial Fibrillation Treatment Market Report
The report on the global Paroxysmal Atrial Fibrillation Treatment market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Paroxysmal Atrial Fibrillation Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast |
|
Base Year |
2021 |
|
Historic Data |
2015–2020 |
|
Forecast Period |
2022–2030 |
|
Segmentation |
Treatment Type (Pharmacological Treatment, Non-pharmacological Treatment, Maze Surgery, and Electric Cardioversion), Technology (Radiofrequency, Laser, Cryotherapy, and Others), End-user (Hospitals, Specialty Clinics, and Others) |
|
Regional Scope |
Regions (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered |
ATRICURE, INC., Abbott, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, CardioFocus, Johnson & Johnson Services, Inc., Medtronic, Rising Pharma Holdings, Inc., Sanofi, and Siemens Medical Solutions USA, Inc. |
Paroxysmal Atrial Fibrillation Treatment Market Segmental Outlook
Based on Treatment Type, the market is segmented into pharmacological treatment, non-pharmacological treatment, maze surgery, and electric cardioversion. The pharmacological treatment segment is expected to hold a considerable share of the market during the forecast, owing to an increase in preference for antiarrhythmic drugs over other surgical methods among patients.
On the basis of Technology, the market is fragmented into radiofrequency, laser, cryotherapy, and others. The radiofrequency segment holds a key share of the market. The increasing prevalence of arrhythmias that cannot be controlled by medication is driving the demand for radiofrequency treatment, which is propelling the segment.
In terms of End-user, the market is classified as hospitals, specialty clinics, and others. The hospital segment is anticipated to expand at a significant CAGR during the forecast period, as the radiofrequency, laser, and cryotherapy techniques are widely performed in hospitals by specialized doctors. Patients suffering from atrial fibrillation mostly prefer hospitals for their treatment due to the presence of specialized doctors and the wide availability of advanced treatment devices.
Regional Outlook
Based on regions, the market is fragmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for a significant share of the market in 2021, due to the growing geriatric population and rising prevalence of cardiovascular diseases in the region.
Key Benefits for Industry Participants & Stakeholders
- In-depth Analysis of the Global Paroxysmal Atrial Fibrillation Treatment Market
- Historical, Current, and Projected Market Size in Terms of Value
- Potential & Niche Segments and Regions Exhibiting Promising Growth Covered
- Industry Drivers, Restraints, and Opportunities Covered in the Study
- Recent Industry Trends and Developments
- Competitive Landscape & Strategies of Key Players
- Neutral Perspective on Global Paroxysmal Atrial Fibrillation Treatment Market Performance
Segments
By Treatment Type
- Pharmacological Treatment
- Non-pharmacological Treatment
- Maze Surgery
- Electric Cardioversion
By Technology
- Radiofrequency
- Laser
- Cryotherapy
- Others
By End-user
- Hospitals
- Specialty Clinics
- Others
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Key Market Players Profiled in the Report
- ATRICURE, INC.
- Abbott
- Boehringer Ingelheim International GmbH.
- Boston Scientific Corporation
- CardioFocus
- Johnson & Johnson Services, Inc.
- Medtronic
- Rising Pharma Holdings, Inc.
- Sanofi
- Siemens Medical Solutions USA, Inc.
Competitive Landscape
-
Manufacturers operating in the global Paroxysmal Atrial Fibrillation Treatment market are ATRICURE, INC., Abbott, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, CardioFocus, Johnson & Johnson Services, Inc., Medtronic, Rising Pharma Holdings, Inc., Sanofi, and Siemens Medical Solutions USA, Inc.
- Market players are pursuing strategies such as acquisitions, product launches, collaborations, and geographic expansion to leverage untapped opportunities in the global Paroxysmal Atrial Fibrillation Treatment market.
Frequently Asked Questions
The base year considered for the global Paroxysmal Atrial Fibrillation Treatment market report is 2021. The complete analysis period is 2015 to 2030, wherein, 2015 to 2020 are the historic years.
The forecasted year considered for the global Paroxysmal Atrial Fibrillation Treatment market report is 2030.
In addition to market size (in US$ Million), company market share (in % for the base year 2021), macroeconomic factors, and supply chain analysis.
The global Paroxysmal Atrial Fibrillation Treatment market remained unaffected by COVID-19, and the production of drugs and medical equipment in manufacturing units continued during the lockdown, which boosted the supply of products for the treatment of Paroxysmal atrial fibrillation in the market.
Major manufacturers include Boehringer Ingelheim International GmbH, Medtronic, Sanofi, and Johnson & Johnson Services, Inc.
Factors such as healthcare spending, GDP, lifestyle diseases, and growth in hospital infrastructure are analyzed in the final report.
According to this Growth Market Reports report, the global Paroxysmal Atrial Fibrillation Treatment market is likely to register a CAGR of 8.8% during the forecast period 2021-2030, with a projected valuation of USD 10,040.2 million by the end of 2030.
The increasing prevalence of Paroxysmal atrial fibrillation in elderly patients, rising prevalence of strokes, and heart failure, and increasing adoption of heart monitoring devices across the globe are the factors expected to drive the market growth during the forecast period.
Factors such as competitive strength and market positioning are key areas considered while selecting top companies to be profiled.
Additional company profiles can be provided on request. For a discussion related to the above findings, click Speak to Analyst
Table Of Content
Chapter 1 Executive SummaryChapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Paroxysmal Atrial Fibrillation Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Paroxysmal Atrial Fibrillation Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Paroxysmal Atrial Fibrillation Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Paroxysmal Atrial Fibrillation Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Paroxysmal Atrial Fibrillation Treatment Market Size & Forecast, 2016-2031
4.5.1 Paroxysmal Atrial Fibrillation Treatment Market Size and Y-o-Y Growth
4.5.2 Paroxysmal Atrial Fibrillation Treatment Market Absolute $ Opportunity
4.6 Global Paroxysmal Atrial Fibrillation Treatment Market: Impact Of Key Regulations
Chapter 5 Global Paroxysmal Atrial Fibrillation Treatment Market Analysis and Forecast By Treatment Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities By Treatment Type
5.1.2 Basis Point Share (BPS) Analysis By Treatment Type
5.1.3 Absolute $ Opportunity Assessment By Treatment Type
5.2 Paroxysmal Atrial Fibrillation Treatment Market Size Forecast By Treatment Type
5.2.1 Pharmacological Treatment
5.2.2 Non-pharmacological Treatment
5.2.3 Maze Surgery
5.2.4 Electric Cardioversion
5.3 Market Attractiveness Analysis By Treatment Type
Chapter 6 Global Paroxysmal Atrial Fibrillation Treatment Market Analysis and Forecast By Technology
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities By Technology
6.1.2 Basis Point Share (BPS) Analysis By Technology
6.1.3 Absolute $ Opportunity Assessment By Technology
6.2 Paroxysmal Atrial Fibrillation Treatment Market Size Forecast By Technology
6.2.1 Radiofrequency
6.2.2 Laser
6.2.3 Cryotherapy
6.2.4 Others
6.3 Market Attractiveness Analysis By Technology
Chapter 7 Global Paroxysmal Atrial Fibrillation Treatment Market Analysis and Forecast By End-user
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities By End-user
7.1.2 Basis Point Share (BPS) Analysis By End-user
7.1.3 Absolute $ Opportunity Assessment By End-user
7.2 Paroxysmal Atrial Fibrillation Treatment Market Size Forecast By End-user
7.2.1 Hospitals
7.2.2 Specialty Clinics
7.2.3 Others
7.3 Market Attractiveness Analysis By End-user
Chapter 8 Global Paroxysmal Atrial Fibrillation Treatment Market Analysis and Forecast by Region
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities by Region
8.1.2 Basis Point Share (BPS) Analysis by Region
8.1.3 Absolute $ Opportunity Assessment by Region
8.2 Paroxysmal Atrial Fibrillation Treatment Market Size Forecast by Region
8.2.1 North America
8.2.2 Europe
8.2.3 Asia Pacific
8.2.4 Latin America
8.2.5 Middle East & Africa (MEA)
8.3 Market Attractiveness Analysis by Region
Chapter 9 Coronavirus Disease (COVID-19) Impact
9.1 Introduction
9.2 Current & Future Impact Analysis
9.3 Economic Impact Analysis
9.4 Government Policies
9.5 Investment Scenario
Chapter 10 North America Paroxysmal Atrial Fibrillation Treatment Analysis and Forecast
10.1 Introduction
10.2 North America Paroxysmal Atrial Fibrillation Treatment Market Size Forecast by Country
10.2.1 U.S.
10.2.2 Canada
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 North America Paroxysmal Atrial Fibrillation Treatment Market Size Forecast By Treatment Type
10.6.1 Pharmacological Treatment
10.6.2 Non-pharmacological Treatment
10.6.3 Maze Surgery
10.6.4 Electric Cardioversion
10.7 Basis Point Share (BPS) Analysis By Treatment Type
10.8 Absolute $ Opportunity Assessment By Treatment Type
10.9 Market Attractiveness Analysis By Treatment Type
10.10 North America Paroxysmal Atrial Fibrillation Treatment Market Size Forecast By Technology
10.10.1 Radiofrequency
10.10.2 Laser
10.10.3 Cryotherapy
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis By Technology
10.12 Absolute $ Opportunity Assessment By Technology
10.13 Market Attractiveness Analysis By Technology
10.14 North America Paroxysmal Atrial Fibrillation Treatment Market Size Forecast By End-user
10.14.1 Hospitals
10.14.2 Specialty Clinics
10.14.3 Others
10.15 Basis Point Share (BPS) Analysis By End-user
10.16 Absolute $ Opportunity Assessment By End-user
10.17 Market Attractiveness Analysis By End-user
Chapter 11 Europe Paroxysmal Atrial Fibrillation Treatment Analysis and Forecast
11.1 Introduction
11.2 Europe Paroxysmal Atrial Fibrillation Treatment Market Size Forecast by Country
11.2.1 Germany
11.2.2 France
11.2.3 Italy
11.2.4 U.K.
11.2.5 Spain
11.2.6 Russia
11.2.7 Rest of Europe
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Europe Paroxysmal Atrial Fibrillation Treatment Market Size Forecast By Treatment Type
11.6.1 Pharmacological Treatment
11.6.2 Non-pharmacological Treatment
11.6.3 Maze Surgery
11.6.4 Electric Cardioversion
11.7 Basis Point Share (BPS) Analysis By Treatment Type
11.8 Absolute $ Opportunity Assessment By Treatment Type
11.9 Market Attractiveness Analysis By Treatment Type
11.10 Europe Paroxysmal Atrial Fibrillation Treatment Market Size Forecast By Technology
11.10.1 Radiofrequency
11.10.2 Laser
11.10.3 Cryotherapy
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis By Technology
11.12 Absolute $ Opportunity Assessment By Technology
11.13 Market Attractiveness Analysis By Technology
11.14 Europe Paroxysmal Atrial Fibrillation Treatment Market Size Forecast By End-user
11.14.1 Hospitals
11.14.2 Specialty Clinics
11.14.3 Others
11.15 Basis Point Share (BPS) Analysis By End-user
11.16 Absolute $ Opportunity Assessment By End-user
11.17 Market Attractiveness Analysis By End-user
Chapter 12 Asia Pacific Paroxysmal Atrial Fibrillation Treatment Analysis and Forecast
12.1 Introduction
12.2 Asia Pacific Paroxysmal Atrial Fibrillation Treatment Market Size Forecast by Country
12.2.1 China
12.2.2 Japan
12.2.3 South Korea
12.2.4 India
12.2.5 Australia
12.2.6 South East Asia (SEA)
12.2.7 Rest of Asia Pacific (APAC)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Asia Pacific Paroxysmal Atrial Fibrillation Treatment Market Size Forecast By Treatment Type
12.6.1 Pharmacological Treatment
12.6.2 Non-pharmacological Treatment
12.6.3 Maze Surgery
12.6.4 Electric Cardioversion
12.7 Basis Point Share (BPS) Analysis By Treatment Type
12.8 Absolute $ Opportunity Assessment By Treatment Type
12.9 Market Attractiveness Analysis By Treatment Type
12.10 Asia Pacific Paroxysmal Atrial Fibrillation Treatment Market Size Forecast By Technology
12.10.1 Radiofrequency
12.10.2 Laser
12.10.3 Cryotherapy
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis By Technology
12.12 Absolute $ Opportunity Assessment By Technology
12.13 Market Attractiveness Analysis By Technology
12.14 Asia Pacific Paroxysmal Atrial Fibrillation Treatment Market Size Forecast By End-user
12.14.1 Hospitals
12.14.2 Specialty Clinics
12.14.3 Others
12.15 Basis Point Share (BPS) Analysis By End-user
12.16 Absolute $ Opportunity Assessment By End-user
12.17 Market Attractiveness Analysis By End-user
Chapter 13 Latin America Paroxysmal Atrial Fibrillation Treatment Analysis and Forecast
13.1 Introduction
13.2 Latin America Paroxysmal Atrial Fibrillation Treatment Market Size Forecast by Country
13.2.1 Brazil
13.2.2 Mexico
13.2.3 Rest of Latin America (LATAM)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Latin America Paroxysmal Atrial Fibrillation Treatment Market Size Forecast By Treatment Type
13.6.1 Pharmacological Treatment
13.6.2 Non-pharmacological Treatment
13.6.3 Maze Surgery
13.6.4 Electric Cardioversion
13.7 Basis Point Share (BPS) Analysis By Treatment Type
13.8 Absolute $ Opportunity Assessment By Treatment Type
13.9 Market Attractiveness Analysis By Treatment Type
13.10 Latin America Paroxysmal Atrial Fibrillation Treatment Market Size Forecast By Technology
13.10.1 Radiofrequency
13.10.2 Laser
13.10.3 Cryotherapy
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis By Technology
13.12 Absolute $ Opportunity Assessment By Technology
13.13 Market Attractiveness Analysis By Technology
13.14 Latin America Paroxysmal Atrial Fibrillation Treatment Market Size Forecast By End-user
13.14.1 Hospitals
13.14.2 Specialty Clinics
13.14.3 Others
13.15 Basis Point Share (BPS) Analysis By End-user
13.16 Absolute $ Opportunity Assessment By End-user
13.17 Market Attractiveness Analysis By End-user
Chapter 14 Middle East & Africa (MEA) Paroxysmal Atrial Fibrillation Treatment Analysis and Forecast
14.1 Introduction
14.2 Middle East & Africa (MEA) Paroxysmal Atrial Fibrillation Treatment Market Size Forecast by Country
14.2.1 Saudi Arabia
14.2.2 South Africa
14.2.3 UAE
14.2.4 Rest of Middle East & Africa (MEA)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Middle East & Africa (MEA) Paroxysmal Atrial Fibrillation Treatment Market Size Forecast By Treatment Type
14.6.1 Pharmacological Treatment
14.6.2 Non-pharmacological Treatment
14.6.3 Maze Surgery
14.6.4 Electric Cardioversion
14.7 Basis Point Share (BPS) Analysis By Treatment Type
14.8 Absolute $ Opportunity Assessment By Treatment Type
14.9 Market Attractiveness Analysis By Treatment Type
14.10 Middle East & Africa (MEA) Paroxysmal Atrial Fibrillation Treatment Market Size Forecast By Technology
14.10.1 Radiofrequency
14.10.2 Laser
14.10.3 Cryotherapy
14.10.4 Others
14.11 Basis Point Share (BPS) Analysis By Technology
14.12 Absolute $ Opportunity Assessment By Technology
14.13 Market Attractiveness Analysis By Technology
14.14 Middle East & Africa (MEA) Paroxysmal Atrial Fibrillation Treatment Market Size Forecast By End-user
14.14.1 Hospitals
14.14.2 Specialty Clinics
14.14.3 Others
14.15 Basis Point Share (BPS) Analysis By End-user
14.16 Absolute $ Opportunity Assessment By End-user
14.17 Market Attractiveness Analysis By End-user
Chapter 15 Competition Landscape
15.1 Paroxysmal Atrial Fibrillation Treatment Market: Competitive Dashboard
15.2 Global Paroxysmal Atrial Fibrillation Treatment Market: Market Share Analysis, 2022
15.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
15.3.1 ATRICURE, INC.
15.3.2 Abbott
15.3.3 Boehringer Ingelheim International GmbH
15.3.4 Boston Scientific Corporation
15.3.5 CardioFocus
15.3.6 Johnson & Johnson Services, Inc
15.3.7 Medtronic
15.3.8 Rising Pharma Holdings, Inc.
15.3.9 Sanofi
15.3.10 Siemens Medical Solutions USA, Inc
Methodology
Related Reports
Some other reports from this category!
Our Clients
